Annual report pursuant to Section 13 and 15(d)

INTANGIBLES - Schedule of intangible assets roll forward (Details)

v3.22.1
INTANGIBLES - Schedule of intangible assets roll forward (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Condensed consolidated statement of operations:    
Balance at beginning $ 15,029 $ 7,377
Isotretinion agreement   4,727
Anti-itch product license acquisition (3) 3,945
Exelderm milestone   400
Amortization expense (2,474) (1,420)
Balance at end 12,552 15,029
Amortization of Intangible Assets 2,474 1,420
2022 $ 1,965  
Renewable Mutual Agreement Term 10 years  
Termination Written Notice Period To Other Party 180 days  
Isotretinion agreement    
Condensed consolidated statement of operations:    
Amortization expense   0
Upfront fees   1,000
Milestone payments payable   500
Amortization of Intangible Assets   0
Long term discounted Payments   300
Finite Lived Intangible Assets Amortization Expense between 2021 through 2023   3,500
Anti-itch product license acquisition    
Condensed consolidated statement of operations:    
Amortization expense $ 0 0
Upfront fees 200  
Amortization of Intangible Assets 0 0
Long term discounted Payments $ 100  
2021   2,800
2022   $ 1,000